Ewing's sarcoma of the bone: ESMO Clinical Recommendations for diagnosis, treatment and follow-up by Paulussen, M. et al.
Annals of Oncology 19 (Supplement 2): ii97–ii98, 2008
doi:10.1093/annonc/mdn103clinical recommendations
Ewing’s sarcoma of the bone: ESMO Clinical
Recommendations for diagnosis, treatment and follow-up
M. Paulussen1, S. Bielack2, H. Ju¨rgens3 & L. Jost4
On behalf of the ESMO Guidelines Working Group*
1Department of Pediatric Oncology/Hematology, University Children’s Hospital Basel (UKBB), Basel, Switzerland; 2Department of Pediatric Oncology and Hemaology,
Olgahospital, Stuttgart, Germany; 3Department of Pediatric Hematology and Oncology, University Children’s Hospital Mu¨nster, Mu¨nster, Germany; 4Department of
Oncology, Kantonsspital, Bruderholz, Germany
incidence
Ewing tumors of bone are the second most common primary
malignant bone cancer in children and adolescents, but are also
seen in adults. The median age at diagnosis is 15 years and
there is a male predilection of 1.5/1. Ewing’s sarcoma (ES)/
peripheral neurectodermal tumors (PNETs) are diagnosed in
white Caucasians at an incidence of 3 per million population
per year, but are very uncommon in African and Asian
populations.
diagnosis
The first symptom is usually pain—often erroneously
attributed to trauma. Plain radiographs in two planes,
complemented by computed tomography (CT) and/or
magnetic resonance imaging (MRI) are indicative of
a malignant tumor. Patients with suggestive findings should be
referred to a center with particular experience in bone sarcoma
before performing a biopsy. The definitive diagnosis is made
by biopsy, providing sufficient material for conventional
histology and molecular biology (fresh, unfixated material). ES/
PNETs are small blue round-cell tumors, PAS- and CD99
(MIC2)-positive. Confirmation of diagnosis by a pathologist
with particular expertise in bone tumors is recommended
[IV, C]. All ES/PNETs are high-grade tumors. While the degree
of neurological differentiation used to be applied to
differentiate classical ES from PNET, newer molecular
biology studies have shown that all ES/PNETs share a common
gene rearrangement involving the EWS gene on chromosome
22. In most cases, a reciprocal translocation t(11;22)(q24;q12)
is found, but t(21;22)(q22;q12) and others may also be found.
staging and risk assessment
Before biopsy, the description of the local extent of the tumor
requires radiographic and CT/MRI of the entire involved bone,
including adjacent joints and soft tissues. For planning of local
therapy, the precise involvement of bone, bone marrow and
soft tissues including the relationship to critical structures like
nerves or vessels, must be specified. A chest CT scan is required
to rule out lung or pleural metastases. The assessment for bone
and bone marrow metastases is to include 99mTc bone
scintigraphy, to detect osseous metastases, and light
microscopic examination of bone marrow aspirates and
biopsies taken at sites distant from the primary tumor. Positron
emission tomography (PET) scanning for bone metastases and
PCR techniques to investigate for bone marrow metastases are
sensitive imaging methods currently under evaluation.
Additional appropriate imaging studies and biopsies should be
taken from suspicious sites, as the exact staging of the disease
has impact on treatment and outcome [III, B].
About 20% of the patients have ES/PNETs of the pelvic
bones, 50% show extremity tumors. ES/PNETs may involve any
bone and (less commonly) soft tissues. Twenty to twenty-five
percent of the patients are diagnosed with metastatic disease
(10% lung, 10% bones, 5% combinations or others).
With surgery or radiotherapy alone, 5-year survival is <10%.
With treatment in current multimodality trials including
chemotherapy, survival approximates to 60–70% in localized
and 20–30% in metastatic disease. Bone metastases confer
a poorer outcome than lung/pleura metastases (<20% versus
20–40% 5-year survival) [IIa, B]. Other known prognostic
factors are tumor size or volume, serum lactate dehydrogenase
(LDH) levels, axial localization or older age (>15 years). Under
treatment, poor histological response to preoperative
chemotherapy, and incomplete or no surgery for local therapy
are further adverse prognostic factors [IIa, B].
treatment plan
As ES/PNETs are rare cancers, and their management is
complex, the accepted standard is treatment in specialized
centers and in the framework of co-operative trials.
localized disease
Multimodal approaches within clinical trials, employing
combination chemotherapy and surgery and/or radiotherapy,
have raised 5-year survival rates from <10% to >60%. All
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current trials employ three to six cycles of initial chemotherapy
after biopsy, followed by local therapy and another six to ten
cycles of chemotherapy usually applied at 3-week intervals.
Treatment duration is thus 8–12 months. Agents considered
most active include doxorubicin, cyclophosphamide,
ifosfamide, vincristine, dactinomycin and etoposide. Virtually
all active protocols are based on four- to six-drug combinations
of these substances. The protocols that have proved to be most
effective include at least one alkylating agent (ifosfamide or
cyclophosphamide) and doxorubicin [Ib, A]. The
incorporation of ifosfamide and etoposide into the treatment
regimen significantly improved the outcome for patients with
non-metastatic ES/PNETs in a randomized trial.
Despite lively debate, complete surgery, where feasible, is
regarded as the best modality of local control. Radiotherapy
should be applied if complete surgery is impossible, and should
be discussed where histological response in the surgical
specimen was poor (i.e. >10% viable tumor cells) [IV, C]. In
one large series it was found that incomplete surgery followed
by radiotherapy was not superior to radiotherapy alone.
Radiotherapy is applied at doses of 40–45 Gy for microscopic
residues and 50–60 Gy for macroscopic disease [III, B].
metastatic and recurrent disease
Outside specific clinical trials, patients with metastatic disease
ought to receive therapy similar to that given for localized
disease, with appropriate local treatment of metastases,
commonly applied as radiotherapy. Several non-randomized
trials have assessed the value of more intensive, time-
compressed or high-dose chemotherapy approaches, followed
by autologous stem-cell rescue, but evidence of benefit, e.g.
resulting from randomized trials, is still lacking [III, B]. Their
use may be justifiable in selected patients with isolated lung
metastases on an individual basis. In patients with lung
metastases, the resection of residual metastases after
chemotherapy, and whole lung irradiation may confer
a survival advantage [III, B]. Patients with bone or bone
marrow metastases and patients with recurrent disease still fare
poorly, with 5-year survival rates of £20%.
The only prognostic factor identified in relapse seems to be
time to relapse: patients relapsing later than 2 years from initial
diagnosis have a better outcome [III, B]. Chemotherapy regimens
in relapse situations are not standardized and are commonly
based on alkylating agents (cyclophosphamide, ifosfamide) in
combination with topoisomerase inhibitors (etoposide,
topotecan). Doxorubicin therapy is usually no longer feasible due
to previously achieved cumulative doses [III, B].
response evaluation
The best radiological method used for local staging should be
repeated after palliative or neoadjuvant chemotherapy and after
definitive local therapy. MRI may provide the most accurate
evaluation of response. In case of neoadjuvant chemotherapy
histologic response should be evaluated in the resection
specimen. The proportion of viable tumor cells provides
prognostic information and may guide the use of further
therapy including radiotherapy in localized disease.
follow-up
Most relapses occur in the first 3 years of follow-up; late
relapses have rarely been observed even after 15 years or longer.
Beside the detection of relapse, long-term sequelae of treatment
are the main concern in long-term follow-up. Impaired renal
function may be observed early in follow-up, but cardiac or
pulmonary damage may become apparent later. Secondary
cancers may arise in irradiated sites. Secondary leukemia,
particularly acute myeloid leukemia, may rarely be observed
independent of previous irradiation as early as 2–5 years after
treatment [III, B]. Follow-up intervals should be 2–3 months
during the first 3 years, 6 months until 5 years and at least once
yearly thereafter. Follow-up is more specifically detailed in
concurrent clinical trial manuals, e.g. EURO-E.W.I.NG. 99.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are
given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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